硫酸肼

硫酸肼
	IUPAC名; Hydrazinium hydrogen sulfate
別名	硫酸聯氨; 硫酸氫肼
識別
CAS編號	10034-93-2
PubChem	24842
ChemSpider	23225
SMILES	O=S(=O)(O)O.NN;
InChI	1/H4N2.H2O4S/c1-2;1-5(2,3)4/h1-2H2;(H2,1,2,3,4);
InChIKey	ZGCHATBSUIJLRL-UHFFFAOYAL
EINECS	233-110-4
性質
化學式	N2H4·H2SO4
外觀	無色結晶
熔點	254 °C
沸點	分解
溶解性（水）	30 g/L (20 °C)
危險性
警示術語	R：R23/24/25-R34-R43-R45-R50-R53
安全術語	S：S45-S53-S60-S61
MSDS	External MSDS
歐盟編號	007-008-00-3
歐盟分類	T N C
	致死量或濃度：
LD50（中位劑量）	601 mg/kg (大鼠經口)
	若非註明，所有數據均出自標準狀態（25 ℃，100 kPa）下。

硫酸肼^[2]是聯氨與硫酸生成的鹽類，指N₂H₅HSO₄和N₂H₆SO₄兩種物質，常寫作N₂H₄·H₂SO₄。

N₂H₆SO₄遇水完全水解，產生N₂H₅HSO₄，而N₂H₅HSO₄尚未分離得到固體。^[3]N₂H₆SO₄固體在室溫下可以以正交晶系或單斜晶系存在。^[4]

性質[編輯]

無色無味鱗狀結晶或斜方結晶。微溶於冷水，易溶於熱水，水溶液呈酸性。不溶於醇。在空氣中穩定，不易吸濕。為強還原劑。不可與鹼類、氧化劑共存。有毒，致癌。^[5]^[6]

硫酸肼受熱分解，其分解產物是硫酸銨和硫酸氫銨。^[3]

製備[編輯]

尿素、次氯酸鈉、液鹼在高錳酸鉀存在下反應，製得肼，經蒸餾，再同硫酸發生中和，生成物經冷卻結晶、過濾、乾燥，製得硫酸肼成品。

{\rm {\ NaOCl+NH_{2}CONH_{2}+2NaOH{\xrightarrow {KMnO_{4}}}N_{2}H_{4}\cdot H_{2}O+}}

{\rm {\ NaCl+Na_{2}CO_{3}}}

{\rm {\ N_{2}H_{4}\cdot H_{2}O+H_{2}SO_{4}\rightarrow N_{2}H_{4}\cdot H_{2}SO_{4}+H_{2}O}}

硫酸氫銨和水合肼反應，也能得到硫酸肼：^[3]

NH₄HSO₄ + N₂H₄·H₂O → N₂H₅HSO₄ + NH₃ + H₂O

用途[編輯]

用作有機合成試劑，用於製取偶氮二異丁腈，以及製造藥品、殺蟲劑、滅菌劑等。化學鍍時用作還原劑。也用作塑膠和橡膠的發泡劑等。

硫酸肼在美國是營養補充劑，用以對抗癌症造成的患者厭食、消瘦等症狀。^[7]^[8]^[9]^[10] 1970年代中期美國的 Joseph Gold^[11]^[12] 首先提出硫酸肼治療法以控制癌患者惡病質的發展。其原理是癌細胞需要靠葡萄糖的糖酵解來產生能量，而此過程的產物乳酸在肝臟中又經過另一耗能過程——糖異生再轉變為葡萄糖。由於肼是化學性質很活潑的化合物，可能在體內對糖異生中的磷酸烯醇式丙酮酸羧化激酶有抑制作用，因此使用硫酸肼可能阻斷糖異生過程，並因此控制惡病質的發展。^[13] 這一替代醫學療法在1990年代中期因《閣樓》成人雜誌創辦人妻子 Kathy Keeton 的宣傳而廣為人知。Keeton 曾用這一方法治療自己的轉移性乳腺癌，^[14] 並聲稱自己因使用這一療法而使壽命延長數年。不過至今，硫酸肼療法的效果仍然受到很大的爭議。

參考資料[編輯]

^ ^1.0 ^1.1 ^1.2 Safety (MSDS) data for hydrazine sulfate
^ 硫酸肼（Hydrazine sulfate）物質安全資料表 (PDF). 國立高雄應用科技大學化工系. [2017-08-14]. （原始內容 (PDF)存檔於2017-08-14）.
^ ^3.0 ^3.1 ^3.2 K. C. Patil. Inorganic Hydrazine Derivatives - Synthesis, Properties and Applications. Wiley, 2014
^ K.C. PATIL, J.P. VITTAL. DSC STUDIES ON THE PHASE TRANSFORMATION OF HYDRAZONIUM SULFATE. Materials Chemistry. 1982. (7): 577-586
^ Hydrazine Hazard Summary, U.S. Environmental Protection Agency, January 2000 [2009-11-24], （原始內容存檔於2009-09-27） .
^ Section 9.2.1, Environmental Health Criteria for Hydrazine, International Programme on Chemical Safety, 1987 [2009-11-24], （原始內容存檔於2010-03-14） .
^ Chlebowski, R. T.; Bulcavage, L.; Grosvenor, M.; et al, Hydrazine Sulfate in Cancer Patients With Weight Loss. A Placebo-Controlled Clinical Experience, Cancer, 1987, 59 (3): 406–10 [2009-11-24], PMID 3791153, （原始內容存檔於2014-11-30） .
^ Brauer, M.; Inculet, R. I.; Bratnager, G.; Marsh, G. D.; Driedger, A. A.; Thompson, R. T., Insulin Protects against Hepatic Bioenergetic Deterioration by Cancer Cachexia. An in-Vivo ³¹P Magnetic Resonance Study, Cancer Research, 1994, 54 (24): 6383–86 [2009-11-24], PMID 7987832, （原始內容存檔於2008-08-21） .
^ Chlebowski, R. T.; Bulcavage, L.; Grosvenor, M.; Oktay, E.; Block, J. B.; Chlebowski, J. S.; Ali, I.; Elashoff, R., Hydrazine Sulfate Influence on Nutritional Status and Survival in Non-Small-Cell Lung Cancer, Journal of Clinical Oncology, 1990, (8): 9–15 [2009-11-24], PMID 1688616, （原始內容存檔於2014-09-28） .
^ Gold, J., Long term complete response in patient with advanced, localized NSCLC with hydrazine sulfate, radiation and Carboplatin, refractory to combination chemotherapy, Proceedings of the American Association for Cancer Research, 1999, (40): 642 . Abstract. （頁面存檔備份，存於互聯網檔案館）
^ Kaegi, Elizabeth, Unconventional therapies for cancer: 4. Hydrazine sulfate. Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative, Canadian Medical Association Journal, 1998, 158 (10): 1327–30, PMID 9614826 .
^ Gold J. Hydrazine sulfate: a current perspective. Nutr Cancer. 1987, 9 (2-3): 59–66. PMID 3104888.
^ Gold, J., Proposed Treatment of Cancer by Inhibition of Gluconeogenesis, Oncology, 1968, 22 (2): 185–207, PMID 5688432 .
^ London, William M., Penthouse's promotion of hydrazine sulfate, July 23, 2006 [2009-11-24], （原始內容存檔於2009-08-17）

[ox-1] 1.0 ^1.1 ^1.2 Safety (MSDS) data for hydrazine sulfate

[2] 硫酸肼（Hydrazine sulfate）物質安全資料表 (PDF). 國立高雄應用科技大學化工系. [2017-08-14]. （原始內容 (PDF)存檔於2017-08-14）.

[hydrazine-3] 3.0 ^3.1 ^3.2 K. C. Patil. Inorganic Hydrazine Derivatives - Synthesis, Properties and Applications. Wiley, 2014

[4] K.C. PATIL, J.P. VITTAL. DSC STUDIES ON THE PHASE TRANSFORMATION OF HYDRAZONIUM SULFATE. Materials Chemistry. 1982. (7): 577-586

[EPA-5] Hydrazine Hazard Summary, U.S. Environmental Protection Agency, January 2000 [2009-11-24], （原始內容存檔於2009-09-27） .

[EHC-6] Section 9.2.1, Environmental Health Criteria for Hydrazine, International Programme on Chemical Safety, 1987 [2009-11-24], （原始內容存檔於2010-03-14） .

[7] Chlebowski, R. T.; Bulcavage, L.; Grosvenor, M.; et al, Hydrazine Sulfate in Cancer Patients With Weight Loss. A Placebo-Controlled Clinical Experience, Cancer, 1987, 59 (3): 406–10 [2009-11-24], PMID 3791153, （原始內容存檔於2014-11-30） .

[8] Brauer, M.; Inculet, R. I.; Bratnager, G.; Marsh, G. D.; Driedger, A. A.; Thompson, R. T., Insulin Protects against Hepatic Bioenergetic Deterioration by Cancer Cachexia. An in-Vivo ³¹P Magnetic Resonance Study, Cancer Research, 1994, 54 (24): 6383–86 [2009-11-24], PMID 7987832, （原始內容存檔於2008-08-21） .

[9] Chlebowski, R. T.; Bulcavage, L.; Grosvenor, M.; Oktay, E.; Block, J. B.; Chlebowski, J. S.; Ali, I.; Elashoff, R., Hydrazine Sulfate Influence on Nutritional Status and Survival in Non-Small-Cell Lung Cancer, Journal of Clinical Oncology, 1990, (8): 9–15 [2009-11-24], PMID 1688616, （原始內容存檔於2014-09-28） .

[10] Gold, J., Long term complete response in patient with advanced, localized NSCLC with hydrazine sulfate, radiation and Carboplatin, refractory to combination chemotherapy, Proceedings of the American Association for Cancer Research, 1999, (40): 642 . Abstract. （頁面存檔備份，存於互聯網檔案館）

[Kaegi-11] Kaegi, Elizabeth, Unconventional therapies for cancer: 4. Hydrazine sulfate. Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative, Canadian Medical Association Journal, 1998, 158 (10): 1327–30, PMID 9614826 .

[12] Gold J. Hydrazine sulfate: a current perspective. Nutr Cancer. 1987, 9 (2-3): 59–66. PMID 3104888.

[13] Gold, J., Proposed Treatment of Cancer by Inhibition of Gluconeogenesis, Oncology, 1968, 22 (2): 185–207, PMID 5688432 .

[14] London, William M., Penthouse's promotion of hydrazine sulfate, July 23, 2006 [2009-11-24], （原始內容存檔於2009-08-17）

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]